M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)

Related Audio: Key messages of the recent report from the STAMPEDE trial platform